Carlo Finelli
A5070851212- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Blood disorders and treatments
- Epigenetics and DNA Methylation
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Protein Degradation and Inhibitors
- Hematological disorders and diagnostics
- Erythrocyte Function and Pathophysiology
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Erythropoietin and Anemia Treatment
- Blood groups and transfusion
- Acute Lymphoblastic Leukemia research
- Pharmacological Effects and Toxicity Studies
- Sarcoma Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Platelet Disorders and Treatments
- Retinoids in leukemia and cellular processes
Istituto di Ematologia di Bologna
1985-2025
Istituti di Ricovero e Cura a Carattere Scientifico
1998-2024
Italian Foundation of Myelodysplastic Syndromes
2016-2024
Azienda USL di Bologna
2021-2024
University of Bologna
2011-2023
Policlinico S.Orsola-Malpighi
2013-2022
Sunnybrook Health Science Centre
2017
Ospedale degli Infermi
2016
Istituto Oncologico Romagnolo
2002-2016
Institute of Hydrology of the Slovak Academy of Sciences
2016
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters cytogenetic abnormalities. Somatic gene mutations not yet used in risk of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular [IPSS-M]), pretreatment diagnostic or peridiagnostic samples from 2957 MDS were profiled 152 genes. Clinical...
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 SMAD3 signaling, showed promising results phase 2 study.In double-blind, placebo-controlled, 3 trial, we randomly assigned patients very-low-risk, low-risk, or intermediate-risk (defined according...
Summary The prognostic value of 12 clinical and haematological parameters, recorded at diagnosis, in myelofibrosis with myeloid metaplasia (MMM) was retrospectively analysed a consecutive series 133 patients followed for minimum 60 months. Multivariate analysis showed that the following features were associated significantly shorter survival: (1) short period time (<13 months) between first symptoms diagnosis; (2) anaemia (haemoglobin <10 g/dl); (3) leucocyte count >12 × 10 9 /l;...
Background Reductions in transfusion requirements/improvements hematologic parameters have been associated with iron chelation therapy transfusion-dependent patients, including those myelodysplastic syndromes; data on these reductions/improvements limited to case reports and small studies.Design Methods To explore this observation a large population of we report post-hoc analysis evaluating response deferasirox cohort iron-overloaded patients syndromes enrolled the Evaluation Patients' Iron...
Mesenchymal stromal cells (MSCs) are an essential element of the bone marrow (BM) microenvironment, playing a crucial function in regulating hematopoietic stem cell proliferation and differentiation. Recent findings have outlined putative role for MSCs hematological malignancy development. So far, conflicting results been collected concerning MSC abnormalities acute myeloid leukemia (AML) myelodysplastic syndrome (MDS). In particular, considerable amount evidence has accumulated strongly...
Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.We examined the effect of on SALL4, a known oncogene that plays an important role in myelodysplastic syndrome other cancers. Paired bone marrow samples were obtained from two cohorts before after treatment agent explore relationships among changes SALL4 expression, response, clinical outcome. Leukemic cell lines low or...
Lipid signaling pathways are involved in cell growth, differentiation, and apoptosis, could have a role the progression of myelodysplastic syndromes (MDS) into acute myeloid leukemia (AML). Indeed, recent studies showed that phosphoinositide-phospholipase (PI-PL)Cbeta1 mono-allelic deletion correlates with higher risk AML evolution. Also, single patient treated azacitidine, DNA methyltransferase inhibitor currently used MDS, displayed direct correlation between PI-PLCbeta1 gene expression...
Epigenetic changes play a role and cooperate with genetic alterations in the pathogenesis of myelodysplastic syndromes (MDS). We conducted phase II multicenter study on combination DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) histone deacetylase valproic acid (VPA) patients higher risk MDS.We enrolled 62 MDS (refractory anemia excess blasts, 39 patients; refractory blasts transformation, 19 chronic myelomanocytic leukemia (CMML), 4 patients) an International Prognostic Scoring...
In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating efficacy and safety this patient population is warranted.The deferasirox was examined a prospective, open-label, single-arm, multicenter International Prognostic Scoring System low- or intermediate-1-risk MDS transfusion-related overload. The effects on hematological...
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis poor and there lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS elderly acute myeloid leukemia, but little data focusing specifically on its efficacy in CMML. In this prospective, phase 2 Italian study, CMML patients received intravenous 20 mg/m2 per day Days 1-5 28-day treatment...
Abstract The Akt/mammalian target of rapamycin (mTOR) signaling pathway is important for both cell growth and survival. In particular, an impaired regulation the Akt/mTOR axis has been strongly implicated in mechanisms related to neoplastic transformation, through enhancement proliferation Myelodysplastic syndromes (MDS) are a group heterogeneous hematopoietic stem disorders characterized by ineffective hematopoiesis high risk evolution into acute myelogenous leukemia (AML). pathogenesis MDS...
Abstract Purpose: This phase II prospective study aimed to evaluate the efficacy and safety of 5-days azacytidine (5d-AZA) in patients with low-risk myelodysplastic syndromes (MDS). Second, single-nucleotide polymorphism (SNP) genetic profile phosphoinositide-phospholipase C (PI-PLC) β1 levels were studied possible biologic markers able predict hematologic response. Experimental Design: The tested a lower intensity schedule azacytidine. treatment plan consisted 75 mg/sqm/d subcutaneous...